Translate
Ideaya Biosciences, Inc.
About
29.10USD-0.44 -1.49%
Closed • Updated at 13:10 GMT+00:00Market Cap$2.56B
Volume450.5K
Beta0.99
RSI46.89
Gross Margin97.96%
Ideaya Biosciences, Inc. — investor relations, events, news, and company updates on 6ix.
Latest News
May 5 2026
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
Apr 30 2026
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
Apr 21 2026
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in 1L HLA*A2-Negative Metastatic Uveal Melanoma
Apr 13 2026
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma
Apr 10 2026
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
Recent Videos
IDYA, IDEAYA Biosciences, Inc. stock prices historical data
Apr 26, 2026
IDEAYA Biosciences Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma
Apr 14, 2026
IDYA, IDEAYA Biosciences, Inc., 2026-04-13, stock prices dynamics, stock of the day
Apr 14, 2026
IDYA Stock Alert: Upside Potential or Major Risk? 🚨
Apr 10, 2026
Community Chat
Ask AI
Try asking